Systemic Infection and Limited Replication of SHIV Vaccine Virus in Brains of Macaques Inoculated Intracerebrally with Infectious Viral DNA  by Smith, Marilyn S. et al.
Virology 301, 130–135 (2002)Systemic Infection and Limited Replication of SHIV Vaccine Virus in Brains
of Macaques Inoculated Intracerebrally with Infectious Viral DNA
Marilyn S. Smith,*,†,1 Yafen Niu,*,† Zhuang Li,*,† Istvan Adany,*,† David M. Pinson,‡ Zhen Qian Liu,*,†
Tanesha Berry,* Darlene Sheffer,*,† Fenglan Jia,*,† and Opendra Narayan*,†
*Marion Merrell Dow Laboratory of Viral Pathogenesis, †Department of Microbiology, Molecular Genetics, and Immunology,
‡Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas 66160
Received December 14, 2001; returned to author for revision February 26, 2002; accepted April 10, 2002
SHIV deleted in two accessory genes, vpunef SHIVPPC, functioned well as a vaccine against later challenge with highly
pathogenic SHIVKU, and it was able to reach the brain after oral inoculation of live virus. In this study, the proviral genome
cloned into a plasmid was inoculated as DNA intracerebrally and spread systemically. Few regions of the brain had
detectable proviral DNA by real-time PCR. Two measures of virus replication, detection of viral mRNA expression and circular
proviral DNA, were negative for those brain regions, with the exception of the infection site in the right parietal lobe, whereas
lymphoid tissues were positive by both measures. Histopathological analyses of all the sampled brain and spinal cordbral inINTRODUCTION
Live SHIV vaccines, created by deletion of regulatory
genes vpu and nef, have been used in macaques in our
laboratory to test proof-of-concept ideas regarding safety
of the agents following oral/systemic routes of inocula-
tion, and definition of the nature of protection against
replication of pathogenic viruses given as challenge
(Lamb-Wharton et al., 1997; Joag et al., 1998; Kumar et al.,
2001). In earlier reports, we had shown that vpuSHIVPPC
(Joag et al., 1998), whose genome was derived originally
by serial passage of SHIV-4 (Li et al., 1992), a chimera of
HIV-1HXBc2, and SIVmac239 in macaques, had proven to be
safe and highly efficacious after a single oral inoculation
of the agent into macaques (Joag et al., 1998; Silverstein
et al., 2000). The virus had undergone productive repli-
cation in lymphoid tissues for about 6 weeks, after which
it could be isolated only rarely from lymph node cells,
even though its DNA persisted for long periods in these
cells (Silverstein et al., 2000; M. Smith et al., unpublished
observations). We then deleted nef from the genome of
this virus, creating vpunef SHIVPPC, and examined the
biological properties of this agent in six macaques that
were inoculated orally with the agent (A. Kumar et al.,
unpublished observations) and in four others into which
the agent had been passaged by serial transfer of blood
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All rights reserved.given by the intravenous route (Mackay et al., 2002).
These 10 animals have been under study for approxi-
mately 3 years and have remained healthy with minimal
concentrations of viral RNA in plasma and normal CD4
cell counts. The vaccine viral DNA persisted in lymph
nodes, and the animals developed CMI responses that
were indistinguishable from the effects of vpuSHIVPPC
described above. In the present study, we examined two
new parameters of infection with vpunefSHIVPPC. First,
we report on use of the infectious DNA of the agent as
inoculum, and second, we evaluated the effects of intra-
cerebral inoculation of this DNA into animals. This route
of inoculation into experimental animals has been
deemed essential by the FDA as one of the criteria of
safety of any live vaccine.
RESULTS AND DISCUSSION
Two juvenile pigtailed macaques (identification num-
bers CD3T and CD20) were inoculated intracerebrally
with 100 l of plasmid DNA (1 g/l) containing the
proviral genome of vpunefSHIVPPC. One week later,
infectious virus was rescued from PBMC, and viral RNA
was found in plasma, as indicated by real-time RT-PCR
(Fig. 1A). This indicated that systemic infection had been
initiated after initial intracerebral infection. Plasma virus
peaked at an average of 105.1 eq/ml at 3 wk p.i. and
declined to 102.9 eq/ml by 6 weeks; it remained low but
detectable (1000 eq/ml) through 4.3 months of infec-
tion. Viral RNA was also present in all CSF samples (withregions did not reveal any abnormalities. Despite intracere
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0042-6822/02 $35.00oculation of the viral DNA, the brain was not targeted for
peak values at 6520 eq/ml in CD3T and 432 in CD20),
indicating much lower concentrations than found in the130
corresponding plasma samples (Fig. 1A). The ratio of
plasma viral RNA to CSF viral RNA at 3 weeks was 190
for macaque CD20 and 20 for macaque CD3T. The peak
viral loads in these animals were similar to those of six
others that had been inoculated orally with live
vpunefSHIVPPC virus (O. Narayan et al., unpublished
observations).
Infectious peripheral blood mononuclear cells (PBMC)
were detected during only the first six weeks of infection
in both animals and peaked at 100 infectious cells/106
PBMCs at 3 weeks p.i. (Fig. 1B). The CD4:CD8 remained
above 1.0 (Fig. 1C), in sharp contrast to the results of
infection with pathogenic SHIVs that caused nearly total
loss of CD4 cells after three weeks (Joag et al., 1997; Liu
et al., 1999).
Peripheral blood was drawn, and inguinal peripheral
lymph nodes were biopsied at 16 weeks for virus culture
and for quantitation of provirus copies and virus RNA
expression. PBMC and LN cell suspensions were de-
pleted of CD8 cells and cocultured with C8166 cells that
were then observed for virus production. Infectivity was
found in LN cells of both animals, but not in the corre-
sponding PBMCs. We also determined the proviral DNA
copy number in DNA extracted from flash-frozen portions
of the lymph node tissue. Copy numbers were deter-
mined as 107 copies/g for CD20 and 78 copies/g for
CD3T. Total RNA was extracted from other portions of the
flash-frozen lymph nodes, and the full-length viral mRNA
was detected by real-time RT-PCR using primers and
Taqman probe to the gag gene. These values were
normalized to the GAPDH copy number also determined
by real-time RT-PCR. The gag:GAPDH ratios for CD20
and CD3T were 0.17 and 0.37, respectively.
The animals were necropsied at six months postinocu-
lation to determine the distribution and quantity, as well as
expression of virus in different organs and tissues. The
animals were exsanguinated and perfused with lactated
Ringer’s solution before any tissue samples were obtained.
Samples from 14 regions of the brain and spinal cord were
examined. These included frontal, parietal, motor, occipital,
and temporal cortices; thalamus; deep white matter; basal
ganglia; cerebellum, brainstem, and hippocampus; cervical,
thoracic, and lumbar regions of the spinal cord. Portions of
each sample were fixed in 4% paraformaldehyde, and par-
affin sections were stained with hematoxylin and eosin.
Scar tissue along the needle tracks at the site of injection in
the brain were detected, and other findings consisted of
focal minimal infiltrate in the leptomeninges of CD20, and
focal negligible infiltrate in meninges of the thalamus of
CD3T. Other lesions in other organ systems are minor.
Real-time PCR was performed on DNA extracted from
lymphoid tissues, including peripheral, bronchial, and
mesenteric lymph nodes, spleen, thymus, and gut-asso-
ciated lymphoid tissue from five regions of the GI tract
(stomach, jejunum, colon, ileum, duodenum), lung, and
from 14 regions of the CNS. The copy numbers obtained
were normalized per microgram DNA to give values for
equivalent cell numbers. Positive copy numbers of pro-
viral DNA were detected in most of the samples of
lymphoid tissues (Fig. 2); four of five GALT samples were
positive in CD20, and one of five samples were positive
in CD3T. Only 5 of the 14 samples of CNS tissue from
CD3T and 3 of the 14 from CD20 were positive for
proviral DNA by real-time PCR. The positive CNS sam-
ples included the sites of inoculation (right parietal
lobes).
To determine whether new rounds of virus replication
had occurred in cells in specific locations, we examined
tissue DNAs of only those samples with a positive real-
time provirus DNA signal for presence of circular proviral
DNA using a nested PCR assay for the circle junction.
This circular provirus genome is a byproduct of the initial
FIG. 1. (A) Cell-free plasma and cerebrospinal fluid viral loads of the
two macaques (CD3T and CD20) at multiple time points were deter-
mined by real-time RT-PCR, using standards covering six orders of
magnitude. The viral loads are shown as viral RNA copies per ml
plasma or per ml CSF. (B) Infectious cells in the peripheral blood were
monitored over the time course of infection in the macaques with a
quantitative culture assay. Dilutions of purified PBMCs were cocultured
with C8166 cells and monitored for infection. The results are shown as
infectious cells per million PBMCs. (C) Time course of CD4:CD8 ratios
in the peripheral blood of the two macaques.
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step of reverse transcription, and its presence has been
interpreted as a sign of newly infected cells (Sharkey et
al., 2000). From macaque CD20 all of the lymphoid tis-
sues tested including the GALT were positive for circular
DNA; all three of the CNS samples that had viral DNA
were negative for circular proviral DNA. From macaque
CD3T, in addition to the lymphoid tissues that were
nearly all positive for circular DNA, the site of DNA
inoculation in the brain was the only CNS region that had
circular provirus DNA; the four other brain regions were
negative (Fig. 2). Thus, whereas proviral DNA could be
detected in some regions of the brain, only lymphoid
tissues had signals indicative of ongoing virus replica-
tion. That the parietal site of infection (including the
needle track) in CD3T was positive, but that of CD20 was
not (needle track not found), could potentially be related
to macrophages attracted to the site of tissue trauma,
which then could be productively infected.
Viral mRNA was detected in the necropsy specimens
by real-time RT-PCR for the gag-containing full-length
transcripts using RNA extracted from lymphoid tissues,
selected brain regions, and the site of DNA inoculation.
All of the lymphoid tissues tested had a positive signal in
the gag reactions, and when normalized to the GAPDH
signal to give a signal per constant cell number, we
found that the mesenteric LN and spleen had the highest
virus mRNA signals and that the other lymphoid tissues
and infection site had close to 10- to 100-fold lower viral
mRNA signals (Fig. 3). RNA signal was not detected in
the CNS samples except at the injection site of the two
FIG. 2. Proviral DNA copies present in various tissues at necropsy were quantified by real-time PCR. The animals were exsanguinated and perfused
prior to obtaining tissue samples. The copy numbers were normalized to 1 g DNA to indicate the results from equivalent cell numbers. Empy bar
spaces represent “not detected.” For detection of newly infected cells in the samples, nested PCR for the short-lived circular proviral DNA by-product
was also performed on samples testing positive for proviral DNA; the results are shown above the bars (/).
FIG. 3. The presence of viral mRNA in tissues obtained at necropsy was detected by a sensitive real-time RT-PCR assay. The animals were
perfused, and tissue samples were flash-frozen in liquid N2 immediately after removal, as described under Materials and Methods. The indicated
lymphoid tissues, the infection site (right parietal lobe), and brain regions with a positive DNA signal (Fig. 2) were chosen for RT-PCR amplification.
CD20 frontal, cerebellum, and brainstem, and CD3T hippocampus were not done.
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animals. When the gag/GAPDH RNA signal was normal-
ized to the proviral DNA copies/g DNA from the same
specimens, the ratios were approximately 105–106 times
higher, respectively, in M-LN and spleen than in the
infection site of CD3T (ratios: M-LN, 1.97  101; spleen,
1.84  102; infection site, 1.04  107) and CD20 (ratios:
M-LN, 4.93  101; spleen 2.3  101; infection site,
2.72  107).
We previously showed that this SHIV deleted in two
accessory genes, vpunef SHIVPPC, functioned well as a
vaccine against later challenge with highly pathogenic
SHIVKU, and that it also was able to reach the brain after oral
inoculation of live virus. This study showed that inoculation
of infectious DNA of vaccine virus, vpunefSHIVPPC, intra-
cerebrally into two animals resulted in rapid development
of systemic infection in both macaques. The infection was
characterized by productive infection in the lymphoid tis-
sues including the thymus, secondary lymphoid tissues in
the abdominal cavity, and the GALT, with the most intense
replication occurring in the spleen and mesenteric lymph
nodes. The CNS also became infected, but only a few
regions among the 14 that were sampled had viral DNA.
None of the positive CNS samples had circular proviral
DNA, with the exception of the injection site (parietal) of one
animal in which the needled track was clearly identified.
The parietal lobe inoculation site of both animals had de-
tectable viral RNA, whereas none of the other CNS sites
with detectable DNA was positive for RNA, suggesting
within the limits of sampling errors that only the cells in this
region had the ability to support replication of the virus,
perhaps due to the stimulation of the monocytes in the area
of tissue damage. Thus, among the 28 samples examined
from the CNS of the two animals, this was the only site that
had viral RNA. Except for focal scarring (with mononuclear
cells) of the brain caused by the needle used for inoculation
of the DNA, there were very minimal pathological changes
in the brains of either of the two animals. The inflammatory
cells in the scar at the inoculation site were probably the
host cells in which viral RNA localized. Similar to the brain,
no pathological changes were observed among the lym-
phoid tissues, and there was no loss of CD4 T cells in
either of the two animals.
Reconstruction of the events that occurred in the ani-
mals, using data from studies on the plasma, the CSF,
and the tissues collected at necropsy, suggested that the
viral DNA in the inoculum caused infection among cells
along the needle path in the brain, as proviral DNA was
readily detected in the site of inoculation. The cells
taking up the plasmid DNA could have been macro-
phages lining blood vessel walls or astrocytes. Mononu-
clear cells from the blood likely responded to the trauma
by infiltration of the brain; one scenario of virus dissem-
ination to the systemic lymphoid compartment would be
for such monocytes to become infected by contact with
resident infected cells and then to transport the virus
back out of the CNS and into contact with highly permis-
sive CD4 T cells.
The results reported here are compatible with known
aspects of neuropathogenesis of lentiviral (LV) infec-
tions. It is now well established that LV encephalitis in
macaques and humans represents end-stage disease
and results from explosive virus replication in macro-
phages in the CNS. Studies on the chronology of neuro-
pathogenic events have shown that the virus invades the
CNS early in the systemic infection and viral DNA can
readily be found in many regions of the brain and spinal
cord. However, examination of brain tissues from ani-
mals that were inoculated with pathogenic SHIV and
killed sequentially thereafter suggested that the infection
was progressive at 3, 10, and 18 days postinoculation,
but it eventually became abortive because brains exam-
ined at 4 months had only a few regions that had viral
DNA. Despite massive virus replication in the lymphoid
tissues, with or without severe loss of CD4 T cells, virus
replication in the brain remains at this minimal level for
long periods. Increase in replication, accompanied with
pathological changes, seems contingent on loss of im-
munocompetence of the host. It is not known whether
the exacerbation of productive replication in the organ at
this time results from reactivation of latent virus or from
a new invasion from the nonneural sites. In the present
study, inoculation of infectious viral DNA directly into the
brain did not expedite neuropathogenic effects beyond
the type of result that develops following infection initi-
ated by inoculation of the virus at a nonneural site. Since
the infection with attenuated virus was not progressive in
the lymphoid tissues, an abortive type of infection in the
CNS was not unexpected. As previously shown with
intracerebral inoculation of pathogenic SIV in rhesus
macaques, intracerebral inoculation did not lead to a
preferential infection of brain tissue (Boche et al., 1995).
MATERIALS AND METHODS
Construction of vpunef SHIV construct and
preparation of DNA stock
The construction of SHIVPPC has been described pre-
viously (Stephens et al., 1998). Briefly, we used SHIVPPC-3,
a plasmid derived after macaque passage of SHIV-
HXBc2 (Li et al., 1992). A 60-bp deletion was introduced
into vpu, and a 205-bp deletion of nef, which deleted the
first 69 amino acids in nef (Joag et al., 1998).
Animal care
Animals were individually housed in an Association for
Assessment and Accreditation of Laboratory Animal
Care international accredited facilities of the University
of Kansas Medical Center.
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Inoculation of macaques
Two pigtailed macaques, 14–15 months old, were
screened serologically for SIV, STLV, and simian retrovi-
rus before inoculation. They were deeply sedated with
ketamine, and holes were drilled in the skull over the
right hemisphere, approximately 1 cm off midline, in the
region of the parietal cortex. The drill bit did not have
contact with the dura mater of the meninges. Infectious
plasmid preparations of vpunef SHIV (100 l of a 1
g/l preparation) were injected into the brain using a
1-in. 27 g needle.
Blood and lymph node samples
Blood samples were collected under ketamine seda-
tion in heparin for infectious virus studies and in EDTA for
quantification of viral RNA by RT-PCR. Blood samples
were collected weekly for the first month, and periodi-
cally until necropsy at 27 weeks p.i. Complete blood
counts (CBCs) were performed to monitor leukocyte pop-
ulations, hematocrit values, and hemoglobin concentra-
tions. Samples were processed as previously described.
Briefly, PBMCs were separated from the buffy coats of
centrifuged blood and mononuclear cells obtained by
centrifugation on gradients of Ficoll–Paque (Pharmacia
Biotech, Piscataway, NJ). Cerebrospinal fluid was col-
lected aseptically from the cisterna magna at the time of
sedation for blood drawing. Two inguinal lymph nodes
were obtained from each animal at 16 weeks p.i. under
ketamine anesthesia. One node was used for prepara-
tion of cell suspension for biological studies, and the
other node was flash-frozen in liquid nitrogen immedi-
ately as a source for RNA and DNA.
Cell cultures
The human T cell line C8166 was used as the indicator
line to measure virus infectivity. These cells were cul-
tured at a concentration of 106/ml in RPMI medium [RPMI
1640 (Life Technologies, Rockville, MD) with 10 mM
HEPES buffer (pH 7.3), 50 mg of gentamicin/ml, 50 mM
2-mercaptoethanol, and 2 mM glutamine] with 10% fetal
bovine serum (FBS). PBMC and LN cell suspensions
were depleted of CD8 T cells as described previously
(Joag et al., 1996) and cocultivated with indicator C8166
cells for rescue of infectious virus.
Fluorescence-activated cell sorting analysis
Samples of whole blood were reacted with fluores-
cent-tagged monoclonal antibodies to CD3, CD4, T,
and CD8 (Dako, Carpinteria, CA), as previously de-
scribed (Wyand et al., 1999). The cells were analyzed on
a fluorescence-activated cell counter FACSCalibur Sys-
tem (Becton-Dickinson, San Jose, CA).
Assessment of virus infectivity
Infectivity in PBMC was measured by inoculation of
serial 10-fold dilutions of the cell suspensions, starting
with 106 cells, into 24-well tissue culture plates contain-
ing 105 indicator C8166 T cells and incubated at 37°C for
7 days. Cells and supernatant fluid in 100 l from each
well were then transferred to another plate, fresh indica-
tor cells added, and the cultures incubated for another 7
days. Cultures were observed for development of syncy-
tial cytopathic effects (CPE). Results were expressed as
the number of infectious cells per 106 PBMC.
Assessment of viral RNA in plasma
Plasma virus RNA loads were performed on RNA ex-
tracted from 500–1000 l EDTA-anticoagulated plasma.
Virus was pelleted from clarified plasma for 1 h at 4°C, at
20,000 g. Virus pellets were resuspended in 140 l PBS,
and the RNA was extracted with the QIAgen viral RNA
minikit (Qiagen, Valencia, CA). RNA samples were sub-
jected to real-time RT-PCR using gag primers and a
Taqman probe (5 fluorescence reporter dye 6-carboxy-
fluorescein and 3 quencher dye 6-carboxytetramethyl-
rhodamine) (Hofmann-Lehmann et al., 2000) using an
ABI Prism 7700 Sequence Detection System (Foster City,
CA). Thermal cycling conditions consisted of 50°C for 2
min for UNG; 60°C for 30 min; 95°C for 10 min; followed
by 44 cycles of 95°C for 15 s and 60°C for 30 s. Prime
RNAse inhibitor was used in the reactions (7.5 U, Brink-
mann-Eppendorf, Westbury, NY), and reaction volumes
were 25 l. Viral RNA equivalents were calculated for 1
ml plasma or CSF. The minimum level of detection for
RNA was 18 copies.
Viral messenger RNA quantitation
Inguinal lymph nodes were biopsied at 16 weeks p.i.
and flash frozen in liquid nitrogen until processing, as
previously described. Necropsy tissue samples were ob-
tained at 27 weeks p.i. Viral gag mRNAs were quantified
using real-time RT-PCR from total RNA isolated from
peripheral lymph nodes or necropsy tissues. Gag mRNA
was determined using the Taqman probe and primers as
described above for the plasma viral RNA determinations
during 44 cycles of RT-PCR (ABI). As a measure of cel-
lular mRNA levels, the GAPDH mRNA copy numbers in
the lymph node RNA samples were also determined by a
real-time RT-PCR Taqman assay over 40 cycles (ABI).
mRNA numbers based on the use of constant standards
were determined in the gag mRNA assays, and as the
amplification efficiencies of the gag and GAPDH targets
can be considered essentially equal [differences in the
slopes (S) of the standard curves was within 0.2], the
gagmRNA levels were normalized to the cellular GAPDH
mRNA number.
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Proviral DNA content in biopsy and necropsy samples
DNA was extracted from flash-frozen peripheral LN or
necropsy samples using Qiagen DNA reagents. DNA
copy number was determined by real-time PCR using the
same gag primers and Taqman probe and the Taqman
Universal PCR Mastermix (Applied Biosystems) in dupli-
cate 25-l reactions in the ABI PRISM 7700 Sequence
Detection System. Proviral copy numbers were normal-
ized to the quantity of total tissue DNA used in the
reaction. DNA real-time conditions were 50°C for 2 min,
95°C for 10 min, followed by 44 cycles of 95°C for 15 s,
60°C for 30 s. Serial 10-fold dilutions of cloned SHIV gag
plasmid over six orders of magnitude were used as
standards. The minimum detectable level of proviral DNA
was 30 copies.
Detection of newly infected cells by circle junction
nested PCR
A nested set of primers was designed using the Prime
program (Genetics Computer Group, 1999) to span the
LTR of the circularized vpunef SHIV proviral DNA (the
circle junction), with the outer primers positioned up-
stream and downstream of the SIV LTR sequence. These
circular molecules are a dead-end byproduct of the re-
verse transcription step occurring in newly infected cells
and can be used as a marker of newly infected cells
(Sharkey et al., 2000). The primers were modified from
previous reports to avoid the nef deletion region in this
virus. The outer primers were cirjntP (5GGGGTATCAGT-
GAGGCCAAA 3) and cirjntQ (5GCACTAAAGGAGCTAA-
GACCGAA 3), resulting in a product of 1347 bp from a
1-LTR circle, and the nested primers included the up-
stream primer inside the LTR (cirjntC: 5CGCTCTGTAT-
TCAGTCGCTC3), and the second downstream from the
LTR (cirjntD: 5AGTTTCTCACGCCCATCTC3), resulting in
a product of 562 bp. The positive control reaction con-
sisted of total DNA extracted from acutely infected CEM
cells in culture.
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